Economic burden of hepatitis C in Egypt: The future impact of highly effective therapies

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 6, 2015, Pages 696-706

  Estes, C ^a   Abdel Kareem, M ^b   Abdel Razek, W ^b   Abdel Sameea, E ^b   Abuzeid, M ^b   Gomaa, A ^b   Osman, W ^b   Razavi, H ^a   Zaghla, H ^b   Waked, I ^b  

^a Center for Disease Analysis   (United States)

^b National Liver Institute   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE COURSE; DRUG COST; EGYPT; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HEPATITIS C; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; DISABLED PERSON; ECONOMICS; EPIDEMIOLOGY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

DISABLED PERSONS; DISEASE PROGRESSION; EGYPT; HEALTH EXPENDITURES; HEPATITIS C; HUMANS; MODELS, ECONOMETRIC; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84939567749     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13316     Document Type: Article

References (48)

1. Sievert W, Altraif I, Razavi HA, et al,. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 (Suppl. 2): 61-80.
2. Lavanchy D,. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
3. Asselah T, Marcellin P,. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 (Suppl. 1): 88-102.
4. Schinazi R, Halfon P, Marcellin P, Asselah T,. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34 (Suppl. 1): 69-78.
5. World Health Organization. Disability adjusted life years (DALY). Available at: http://www.who.int/healthinfo/global-burden-disease/metrics-daly/en (accessed 14 November 2014).
6. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl. 1): 34-59.
7. Central Agency for Public Mobilization and Statistics (CAPMAS). Estimates of midyear population by age groups, 2012 [cited: November 21 2013]. Available at: http://www.capmas.gov.eg/pdf/Electronic%20Static%20Book2013/english/population/untitled1/pop.aspx (accessed 14 November 2014).
8. United Nations; Department of Economic and Social Affairs; Population Division. World Population Prospects: The 2010 Revision, Volume I: Comprehensive Tables. ST/ESA/SER.A/313, 2011.
9. El-Zanaty F, Way A,. Egypt Demographic and Health Survey, 2008. Cairo, Egypt: Ministry of Health and Population, Demographic and Health Survey (EDHS), 2009.
10. Cowgill KD, Loffredo CA, Eissa SA, et al,. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004; 33: 1034-9.
11. Goldman L, Ezzat S, Mokhtar N, et al,. Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 2009; 20: 981-7.
12. Gouda I, Nada O, Ezzat S, et al,. Immunohistochemical detection of hepatitis C virus (genotype 4) in B-cell NHL in an Egyptian population: correlation with serum HCV-RNA. Appl Immunohistochem Mol Morphol 2010; 18: 29-34.
13. Soliman A, Boffetta P,. Lymphoma and leukemia. In:, Freedman LS, Edwards BK, Ries LAG, Young JL, eds. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared With US SEER, Chapter 14. Bethesda, MD: National Cancer Institute. NIH Pub. No. 06-5873, 2006; 131-40. Available at: http://seer.cancer.gov/archive/publications/mecc/mecc-monograph.pdf (accessed 14 November 2014).
14. Herzog CM, Dey S, Hablas A, et al,. Geographic distribution of hematopoietic cancers in the Nile delta of Egypt. Ann Oncol 2012; 23: 2748-55.
15. Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-Hamid M,. Association of HCV with diabetes mellitus: an Egyptian case-control study. Virol J 2011; 8: 367.
16. White DL, Ratziu V, El-Serag HB,. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-44.
17. Lee MH, Yang HI, Lu SN, et al,.; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a long-term prospective study. J Infect Dis 2012; 206: 469-77.
18. van der Meer AJ, Veldt BJ, Feld JJ, et al,. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.
19. Waked I, Doss W, El-Sayed MH, et al,. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014; 15: 45-52.
20. Murray CJL, Lopez AD,. The Global Burden of Disease. Geneva: WHO, Harvard School of Public Health, World Bank, 1996.
21. WHO Health Statistics and Information Systems, 2014. Available at: www.who.int/healthinfo/bodreferencedalycalculationtemplate.xls (accessed 14 November 2014).
22. WHO Global Health Observatory Data Repository, 2014. Available at: http://apps.who.int/gho/data/node.main (accessed 14 November 2014).
23. Gomaa AI, Hashim MS, Waked I,. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS ONE 2014; 9 (3): e90929.
24. Mathers C, Vos T, Stevenson C,. The burden of disease and injury in Australia. AIHW cat. no. PHE 17. Canberra: AIHW, 1999. Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442459196 (accessed 14 November 2014).
25. Stouthard M, Essink-Bot ML, Bonsel GJ, et al,. Disability Weights for Diseases in the Netherlands. Rotterdam, Netherlands: Erasmus University Press, 1997.
26. World Bank. 2014. Egypt, Arab Rep. Available at: http://data.worldbank.org/country/egypt-arab-republic March 13, 2014 (accessed 14 November 2014).
27. CAPMAS: Annual statistics of jobs, salaries, and work hours for 2012. Available at: http://www.capmas.gov.eg/pdf/news/Twzf2012.pdf (accessed 14 November 2014).
28. US Department of Transportation. Revised Departmental Guidance 2013: Treatment of the Value of Preventing Fatalities and Injuries in Preparing Economic Analyses, 2013. Available at: http://www.dot.gov/sites/dot.gov/files/docs/VSL%20Guidance-2013.pdf (accessed 14 November 2014).
29. The White House, US Government. 2013 Draft Report to Congress On the Benefits and Costs of Federal Regulations and Agency Compliance with the Unfunded Mandates Reform Act. Available at: http://www.whitehouse.gov/sites/default/files/omb/inforeg/2013-cb/draft-2013-cost-benefit-report.pdf (accessed 14 November 2014).
30. WHO: Commission on Macroeconomics and Health. Macroeconomics and Health: Investing in Health for Economic Development, Sachs J, ed. Geneva: WHO, 2001.
31. Viscusi WK,. Policy challenges of the heterogeneity of the value of statistical life. Foundations Trends Microecon 2010; 6: 99-172.
32. Suhrcke M,. Chronic disease: alternative perspective. Chapter 3.2. In:, Lomborg B, ed. Global Problems: Smart Solutions, Costs and Benefits. Cambridge: Cambridge University Press, 2013; 180-5.
33. WHO Global Health Observatory Data Repository. Life tables by country: Egypt, 2014. Available at: http://apps.who.int/gho/data/view.main.60500 (accessed 14 November 2014).
34. Musgrove P, Fox-Rushby J,. Cost-Effectiveness Analysis for Priority Setting. Chapter 15, 271-286. In:, Jamison DT, Breman J, Measham A, Alleyne G, Claeson M, Evans D, Jha P, Mills A, Musgrove P, eds. Disease Control Priorities in Developing Countries. Second Edition: Oxford University Press and The World Bank, 2006.
35. Goldie SJ, Yazdanpanah Y, Losina E, et al,. Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 2006; 355: 1141-53.
36. WHO: Cost-effectiveness thresholds. Available at: http://www.who.int/choice/costs/CER-thresholds/en/ (accessed 14 November 2014).
37. Bruggmann P, Berg T, Ovrehus AL, et al,. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21 (Suppl. 1): 5-33.
38. Miller TR,. Variations between countries in values of statistical life. J Transport Econ Policy 2000; 34: 169-88.
39. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013; 36: 1033-46.
40. World Bank: Health expenditure, total (% of GDP). Available at: http://data.worldbank.org/indicator/SH.XPD.TOTL.ZS (accessed 14 November 2014).
41. Myers RP, Krajden M, Bilodeau M, et al,. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol 2014; 28: 243-50.
42. Gordon SC, Pockros PJ, Terrault NA, et al,. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-60.
43. Davis KL, Mitra D, Medjedovic J, Beam C, Rustgi V,. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 2011; 45: e17-24.
44. Younossi Z, Henry L,. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41: 497-520.
45. Cacoub P, Poynard T, Ghillani P, et al,. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999; 42: 2204-12.
46. Charles ED, Dustin LB,. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-24.
47. Doss W,. Egyptian National Control Strategy for Viral Hepatitis 2008-2012. Arab Republic of Egypt: Ministry of Health and Population, National Committee for the Control of Viral Hepatitis, 2008.
48. Smith BD, Morgan RL, Beckett GA, et al,. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.